Nyrada Inc - Annual Report 2021

NYRADA INC (ASX:NYR) 12 Peter Marks Non-Executive Director, joined the Board in August 2017 Peter Marks has over 35 years' experience in corporate advisory and investment banking. Throughout his long career, he has specialised in capital raising, IPOs, cross border M&A transactions, corporate underwriting, and venture capital transactions for companies in Australia, the US and Israel. He has been involved in a broad range of transactions with a special focus on the life sciences, biotechnology, medical technology and high-tech segments. Peter has served as both an Executive and Non-Executive Director of several different entities which have been listed on the ASX, NASDAQ, and AIMmarkets. Peter is currently a Director of Alterity Therapeutics Limited (ASX:ATH and NASDAQ:ATHE), Non-Executive Director of Noxopharm Limited (ASX: NOX) and Non-Executive Director of Elsight Ltd (ASX:ELS). Until 31 March 2020, he was also a Non-Executive Director of Fluence Corporation Ltd (ASX: FLC). Peter holds an MBA from the University of Edinburgh, Scotland, a Bachelor of Economics, a Bachelor of Laws and a Graduate Diploma in Commercial Law. Interest in shares and options 250,000 shares and 2,600,000 unlisted options Special responsibilities Member of the Audit and Risk Committee Directorship held in other listed entities (last 3 years) Alterity Therapeutics Limited (ASX: ATH) - current Noxopharm Limited (ASX:NOX) - current Elsight limited (ASX:ELS) - current Fluence Corporation Limited (ASX:FLC) - resigned 31 March 2020 Christopher Cox Non-Executive Director, joined the Board in November 2019 Christopher Cox is a Co-Founder and Managing Partner of Population Health Partners, L.P., a global private equity firm focused on innovative therapeutics with the potential to transform health outcomes for populations. Prior to that, from January 2012 to February 2020, Chris was a partner at Cadwalader, Wickersham & Taft LLP, where he also served as the Chairman of Cadwalader’s Corporate Department and as a member of its Management Committee. Chris remains a Senior Attorney of Cadwalader. From February 2016 to March 2019, Chris was seconded to The Medicines Company, a global biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was responsible for business development and strategy. Prior to January 2012, Chris was a partner at Cahill Gordon & Reindel LLP. Chris also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a private investment holding company with interests in life sciences, entertainment and technology. Chris received both his undergraduate degree and J.D. from the University of Missouri. Interest in shares and options 1,425,000 shares and 1,800,000 unlisted options Special responsibilities Chair of the Remuneration and Nomination Committee Directorship held in other listed entities (last 3 years) N/A